COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
1 . A composition comprising a type II anti-CD20 antibody and a proteasome inhibitor.
2 . A composition according to claim 1 , wherein said proteasome inhibitor has an IC50 of the anti-proteasome inhibitory activity of 5 μM or less.
3 . A composition according to claim 1 , wherein said type II anti-CD20 antibody has a ratio of the binding capacities to CD20 on Raji cells (ATCC-No. CCL-86) of said type II anti-CD20 antibody compared to rituximab of 0.3 to 0.6
4 . A composition according to claim 1 , wherein said type II anti-CD20 antibody is a humanized B-Ly1 antibody.
5 . A composition according to claim 1 , wherein said type II anti-CD20 antibody has increased antibody dependent cellular cytotoxicity (ADCC).
6 . A composition according to claim 1 , wherein at least 40% of the oligosaccharides of the Fc region of said type II anti-CD20 antibody are non-fucosylated.
7 . A composition according to claim 1 , wherein said proteasome inhibitor is selected from the group consisting of peptide aldehydes, peptide boronates, peptide epoxyketones, and salinosporamide A.
8 . A composition according to claim 1 , wherein said proteasome inhibitor is bortezomib.
9 . A composition according to claim 1 , further comprising one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds that enhance the effects of such agents.
10 . A kit comprising a type II anti-CD20 antibody and a proteasome inhibitor for the combination treatment of a patient suffering from a CD20 expressing cancer.
11 . A method for the treatment of a CD20 expressing cancer in a patient comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
12 . A method according to claim 11 wherein said type II anti-CD20 antibody is a humanized B-Ly1 antibody, said proteasome inhibitor is bortezomib, and said CD20 expressing cancer is B-Cell Non-Hodgkin's lymphoma.